Samsung Biologics just made its biggest move yet. The South Korean contract manufacturing giant launched an all-cash bid of 1.46 billion Swiss francs, roughly $1.81 billion, to acquire Switzerland’s PolyPeptide Group AG.
If you've been following the pharmaceutical market, this deal shouldn't come as a total shock, but the scale of it is staggering. It marks the largest overseas acquisition ever made by a South Korean biotech firm. Read more on a related issue: this related article.
The move isn't just about getting bigger for the sake of it. It's a calculated attempt to control the supply chain for GLP-1 weight loss and diabetes treatments, two categories currently consuming the entire biotech conversation.
The Deal Details on the Table
Samsung Biologics offered 44.31 Swiss francs per share for all outstanding shares of PolyPeptide Group. That's a 6.1% premium over Friday's closing price, but more importantly, it represents a 40% premium to where the stock traded in April before takeover whispers surfaced. Additional analysis by Financial Times highlights related views on this issue.
PolyPeptide's board didn't hesitate. They unanimously recommended that shareholders accept the cash offer.
The biggest shareholder, Draupnir Holding, already signed on. Draupnir owns 55.65% of PolyPeptide and agreed to tender every single share into the offer. Since Draupnir is linked to Swedish billionaire Frederik Paulsen through the Cryosphere Foundation, getting their approval early basically cleared the runway.
Samsung Biologics plans to launch the official tender offer by late August 2026. They expect to close the acquisition before the year ends, buy out remaining minority holders, and squeeze the company off the SIX Swiss Exchange.
Why Peptides Are Driving the Move
For years, Samsung Biologics built its reputation as a power player in monoclonal antibodies and antibody-drug conjugates (ADCs). Their massive production campus in Songdo, South Korea, turns out vast quantities of biologic drugs for global big pharma.
Antibodies aren't peptides, though.
Peptides are shorter chains of amino acids. They require distinct chemical synthesis processes, specialised purification setups, and specific quality control infrastructure. Building peptide facilities from scratch takes years of capital investment and regulatory validation.
By buying PolyPeptide Group, Samsung skips the line entirely.
PolyPeptide brings over 70 years of experience in custom peptide manufacturing. They have produced more than 1,000 therapeutic peptides over their long history. More importantly, they own six active operational plants spread across:
- Sweden
- Belgium
- France
- The United States
- India
Instead of waiting half a decade to construct facilities, Samsung buys a turnkey global operations footprint instantly.
The GLP-1 Gold Rush
You can't talk about peptides in 2026 without talking about metabolic health. GLP-1 receptor agonists like semaglutide and tirzepatide have rewritten drugmaker balance sheets.
Demand for these injectable and oral obesity treatments completely outstripped world manufacturing capacity over the last three years. Drug companies are desperate for reliable contract development and manufacturing organisations (CDMOs) capable of producing complex peptide active pharmaceutical ingredients (APIs) at scale.
I've watched drugmakers scramble for capacity every quarter. The bottleneck hasn't been customer demand; it has been factory floor availability.
Samsung Biologics CEO John Rim saw that gap. By combining Samsung's massive industrial scale with PolyPeptide's specialised chemical expertise, Samsung positions itself as a one-stop supplier for metabolic medicine giants.
Expanding Beyond South Korea
This acquisition continues a pattern. In December 2025, Samsung Biologics bought GSK’s Human Genome Sciences facility in Rockville, Maryland, for $280 million to establish a firm physical manufacturing base inside the United States.
Owning plants in Maryland, Western Europe, and India gives Samsung geographic diversification that pharmaceutical clients demand. Drug companies don't like putting all their manufacturing eggs in one geographical basket, especially given geopolitical friction and complex supply chain rules.
Samsung's total bioreactor capacity in Songdo is set to climb from 784,000 liters to over 1.32 million liters as new plants open through 2032. Adding PolyPeptide’s six facilities complements those giant Korean vats with localized European and American peptide production.
Market Reaction and Investors' Hesitation
Wall Street and local exchanges reacted with immediate nuance. Shares of Samsung Biologics dropped around 3.4% in Seoul right after the announcement.
Why did the stock dip on a clear strategic expansion?
First, cash payouts of $1.81 billion reduce short-term liquidity. Investors often react cautiously to big cash outflows, even when the strategic rationale is solid.
Second, integrating a 70-year-old European organisation with a fast-moving South Korean corporate culture takes real work. Merging management teams across Switzerland, France, Sweden, and the US isn't effortless.
The market drop looks short-sighted to me. The underlying commercial demand for peptide APIs guarantees high plant utilization rates for years to come.
What Happens Next for Pharma Executives and Investors
If you hold shares or manage supply chains in biotech, keep these milestones on your radar over the next six months:
- Watch the late August 2026 formal tender launch to verify regulatory filings in Switzerland.
- Track the minimum acceptance threshold; Samsung needs two-thirds of total shares, though Draupnir’s 55.65% stake makes reaching that threshold almost certain.
- Monitor antitrust clearances across European Union and US regulators during autumn.
- Prepare for the full delisting of PolyPeptide Group from the SIX Swiss Exchange by December 2026.
Samsung Biologics just signaled that contract manufacturing is no longer just about building bigger stainless-steel tanks. It's about securing every technical format a drug developer might need.
